BDBM173375 US10323032, Example 88::US9096596, 88::US9604982, Example 88

SMILES C[C@@H]1Cc2c(CN1C(=O)c1ccc(Cl)cc1F)nc(C)nc2-c1ccn[nH]1

InChI Key

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 173375   

TargetP2X purinoceptor 7(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  1.10E+4nMpH: 7.4Assay Description:1321N1 cells expressing the recombinant human, rat or mouse P2X7 channel was cultured in HyQ DME/(HyClone/Dulbecco's Modified Eagle Medium) high gluc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Rattus norvegicus (Rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  8.77E+3nMpH: 7.4Assay Description:1321N1 cells expressing the recombinant human, rat or mouse P2X7 channel was cultured in HyQ DME/(HyClone/Dulbecco's Modified Eagle Medium) high gluc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  1.10E+4nMAssay Description:1321N1 cells expressing the recombinant human or rat P2X7 channel was cultured in HyQ DME/(HyClone/Dulbecco's Modified Eagle Medium) high glucose...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Rattus norvegicus (Rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  8.77E+3nMAssay Description:Human or rat P2X7-1321N1 cells were collected and frozen @ −80° C. On the day of the experiment, cell membrane preparations were made according...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  1.10E+4nMAssay Description:1321N1 cells expressing the recombinant human or rat P2X7 channel was cultured in HyQ DME/(HyClone/Dulbecco's Modified Eagle Medium) high glucose...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Rattus norvegicus (Rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  8.77E+3nMAssay Description:Human or rat P2X7-1321N1 cells were collected and frozen @ −80° C. On the day of the experiment, cell membrane preparations were made according...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Rattus norvegicus (Rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  17nMAssay Description:Antagonist activity at rat P2X7 receptor expressed in 1321N1 cells assessed as inhibition of BzATP-induced calcium mobilization incubated for 30 mins...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP2X purinoceptor 7(Rattus norvegicus (Rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  8.77E+3nMAssay Description:1321N1 cells expressing the recombinant human or rat P2X7 channel was cultured in HyQ DME/(HyClone/Dulbecco's Modified Eagle Medium) high glucose...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  19nMAssay Description:Antagonist activity at human recombinant P2X7 receptor expressed in 1321N1 cells assessed as inhibition of BzATP-induced calcium mobilization incubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP2X purinoceptor 7(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  19nMAssay Description:Antagonist activity at human recombinant P2X7 receptor expressed in 1321N1 cells assessed as inhibition of BzATP-induced calcium mobilization incubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP2X purinoceptor 7(Rattus norvegicus (Rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  17nMAssay Description:Antagonist activity at rat P2X7 receptor expressed in 1321N1 cells assessed as inhibition of BzATP-induced calcium mobilization incubated for 30 mins...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Janssen Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Janssen Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP2X purinoceptor 7(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM173375(US10323032, Example 88 | US9096596, 88 | US9604982...)
Affinity DataIC50:  1.10E+4nMAssay Description:1321N1 cells expressing the recombinant human or rat P2X7 channel was cultured in HyQ DME/(HyClone/Dulbecco's Modified Eagle Medium) high glucose...More data for this Ligand-Target Pair
In DepthDetails US Patent